Accueil / Communiqués / Triumvira Immunologics to Present at CAR-T Congress EU in London, UK

Triumvira Immunologics to Present at CAR-T Congress EU in London, UK

Tuesday, January 29th 2019 at 12:00pm UTC

AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)– class= »bwalignl »>
, a privately held biopharmaceutical company developing
a novel platform for engineering T cells to attack cancers, today
announced that Dr. Paul Lammers, President & CEO, will both present and
moderate a round table discussion at the CAR-T Congress EU, to be held
in London UK on January 30-31. The invitations acknowledge Triumvira’s
expertise in the novel engineering of T cells for the potential
treatment of hematological malignancies and solid tumors.

The CAR-T Congress EU is a forum focused on discovering, translating,
developing, and commercializing CAR-T into viable and accessible
therapies. CAR-T cell therapies have shown transformational activity in
hematological malignancies. However, despite the tremendous success so
far, there are still hurdles to overcome before CAR-T can be effective
in mainstream oncology beyond hematological malignancies. The European
CAR-T Congress’ mission is to address the opportunities and challenges
that presently face the CAR-T field and maximize the potential of this
ground-breaking therapy. As Triumvira’s proprietary T cell Antigen
Coupler (TAC) technology is biologically distinct from CAR-T and has the
potential to be a next generation solution, Triumvira seeks to address
some of the challenging areas for existing therapies in hematological
malignancies and expand treatment activity to solid tumors.

Paul Lammers, MD, MSc, President and Chief Executive Officer will
present and lead a round table discussion at CAR-T Congress EU as

Date: Wednesday January 30, 2019

Time: 14:20 (GMT)

Venue: Millennium Gloucester Hotel, 4-18 Harrington Gardens, Kensington,
London, SW7 4LH

Presentation: Triumvira’s TAC-T cell Technology: A Step Forward in
Adoptive T Cell Therapy.

Date: Thursday January 31, 2019

Time: 10:30 (GMT)

Venue: Millennium Gloucester Hotel, 4-18 Harrington Gardens, Kensington,
London, SW7 4LH

Moderating Round Table: Critical Challenges Facing CAR-T Therapy:
Strengthening CAR-T for Solid Tumors.

About Triumvira Immunologics

Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company
co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and
Bloom Burton & Co., with the vision of developing novel T cell therapies
that are safer and more efficacious than current gene therapy cancer
treatments, including chimeric antigen receptor (CAR) and engineered T
cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler
(TAC) technology recruits the entire natural T cell receptor and is
independent of the Major Histocompatibility Complex (MHC), allowing for
the development of better therapies for a broader range of patients with
solid or liquid malignancies and with diseases other than cancer. With
operations spanning North America, our corporate offices are in Austin,
Texas, and our research facilities in Hamilton, Ontario. For more
information, visit or
send email inquiries to


Katie Gallagher +1 617-374-8800, Ext. 109
Manager, PR and Marketing

Source: Triumvira Immunologics, Inc.

Voir aussi

Maverick Therapeutics to Unveil Pre-Clinical Data on Novel COBRATM Platform at American Association for Cancer Research 2019 Annual Meeting

Saturday, March 30th 2019 at 12:00pm UTC – Pre-clinical Data Characterize the Conditional and Potent …